FDA Approves At-Home Option for Skyrizi Induction Dose in Crohn's Disease

The U.S. Food and Drug Administration has approved an at-home option for the induction dose of risankizumab-rzaa for adults with moderate to severe Crohn's disease. The option allows this dose to be administered at home instead of at a medical facility.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The approval covers the induction dose of risankizumab-rzaa administered subcutaneously.

  «FDA approved an at-home induction option for risankizumab-rzaa in adults with moderate-to-severe Crohn»

  Pharmaceutical Executive • HCPLive
• The approval is directed at adults with moderate to severe Crohn's disease.

  «اعتمدت إدارة الغذاء والدواء الأمريكية خيارًا منزليًا للجرعة الأولية من دواء risankizumab-rzaa لدى البالغين»

  Pharmaceutical Executive
• The approved option allows the induction dose to be given at home instead of at a medical facility.

  «ويتيح الخيار إعطاء هذه الجرعة في المنزل بدلًا من المنشأة الطبية.»

  Pharmaceutical Executive

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms